Renalytix plc (LSE: RENX; OTCQB: RNLXY), a precision medicine diagnostics company focused on kidney disease, has announced that SP Angel Corporate Finance LLP and Oberon Capital have both initiated equity research coverage on the company. The announcement, made on 9 November 2026, confirms that research notes from both brokers are available via Research Tree and each firm's dedicated research portal. Initiation of coverage by two brokers simultaneously may draw additional investor attention to the company's commercial-stage kidney diagnostics business.

Key Points

  • Renalytix plc (LSE: RENX; OTCQB: RNLXY) is an AI-enabled in vitro diagnostics company focused on kidney disease management.
  • SP Angel Corporate Finance LLP and Oberon Capital have both initiated equity research coverage on Renalytix simultaneously.
  • Research notes are publicly available on Research Tree, the SP Angel website, and the Oberon Capital research portal.
  • Investors may watch for how the initiation of dual broker coverage influences institutional awareness of RENX's KidneyIntelX commercial programme.

SP Angel and Oberon Capital Initiate Joint Coverage of Renalytix on Research Tree

Both SP Angel Corporate Finance LLP and Oberon Capital have published inaugural research notes on Renalytix plc, with coverage accessible through the Research Tree platform as well as each broker's own research portal. SP Angel serves as Renalytix's Nominated Adviser and joint broker, while Oberon Capital acts as joint broker. The dual initiation means that two separate analyst teams are now providing independent assessments of the company, potentially broadening the investment community's access to structured analysis of Renalytix's commercial and scientific progress. The company did not disclose the target prices or ratings contained within either research note.

KidneyIntelX Technology Targets Diabetic Kidney Disease in US and UK Markets

Renalytix's core commercial product, kidneyintelX.dkd, is an artificial intelligence-enabled in vitro diagnostic tool designed to assess patient risk for progressive decline in kidney function at the earliest stages of diabetic kidney disease. The technology supports clinical decision-making by enabling care teams to prioritise treatment interventions. The announcement states that the product has received FDA authorisation and Medicare reimbursement, and is offered commercially throughout the United States. The company operates across both London and New York, reflecting its dual-market listing and international commercial ambitions.

Diabetic Kidney Disease Affects an Estimated 23 Million People Across the US and UK

According to the company's own disclosure, unrecognised and uncontrolled diabetic kidney disease affects approximately 15 million people in the United States and 8 million in the United Kingdom, representing a significant unmet medical need and a substantial addressable market for Renalytix's diagnostic platform. The scale of the condition in both countries underlines the potential commercial opportunity for kidneyintelX.dkd, though the company did not disclose current revenue figures or volume of tests conducted in the announcement.

Renalytix's Medicare Reimbursement Status Underpins US Commercial Model

A key commercial milestone for Renalytix is the Medicare reimbursement status secured for kidneyintelX.dkd, which the announcement confirms is in place for commercial deployment across the United States. Reimbursement coverage is a critical enabler for adoption of diagnostic tests within the US healthcare system, as it removes a significant financial barrier for both clinical providers and patients. Investors may consider reimbursement reach and clinical uptake rates as central metrics when evaluating the company's growth trajectory, although no updated commercial figures were provided in this announcement.